Prezatide copper acetate | CAS:130120-57-9

We serve Prezatide copper acetate CAS:130120-57-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Prezatide copper acetate

Chemical Name:Prezatide copper acetate
CAS.NO:130120-57-9
Synonyms:Prezatide copper acetate
(2S)-6-amino-2-[[(2S)-2-[(2-aminoacetyl)amino]-3-(1H-imidazol-5-yl)propanoyl]amino]hexanoic acid
 
Physical and Chemical Properties:
Boiling Point 831ºC at 760mmHg
Molecular Formula C16H28CuN6O6
Molecular Weight 463.97600
Flash Point 456.4ºC
 
Specification:
Appearance:Blue powder
Assay:≥95.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Promotes ‘extra large’ collagen aggregates degradation, more regularly collagen synthesis, elastin, proteoglycans, glycosaminoglycans production and anti-inflammatory and antioxidant responses.



Contact us for information like Prezatide copper acetate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(2S)-6-amino-2-[[(2S)-2-[(2-aminoacetyl)amino]-3-(1H-imidazol-5-yl)propanoyl]amino]hexanoic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Prezatide copper acetate Use and application,(2S)-6-amino-2-[[(2S)-2-[(2-aminoacetyl)amino]-3-(1H-imidazol-5-yl)propanoyl]amino]hexanoic acid technical grade,usp/ep/jp grade.


Related News: In 2004, the National Development and Reform Commission, the former Ministry of Health, and the Ministry of Finance jointly formulated and promulgated the Administrative Measures for the Configuration and Use of Large Medical Equipment. This method uses X-ray electronic computer tomography (CT) devices and medical magnetic resonance imaging equipment, digital subtraction angiography X-ray machines of 800 mA or more as the management products of large-scale medical equipment, Purchase and use need to be reported to the provincial health administrative department for approval before approval. However, in recent years, with the comprehensive coverage of medical insurance, such basic medical facilities are being widely popularized, and the relevant implementation rules have directly linked the number of equipment to the number of doctors. Therefore, as the demand for imaging equipment continues to increase, it will have a greater boosting effect on the upstream contrast agent and its raw material market.5,6,7,8-Tetrahydroquinoxaline manufacturer In 2004, the National Development and Reform Commission, the former Ministry of Health, and the Ministry of Finance jointly formulated and promulgated the Administrative Measures for the Configuration and Use of Large Medical Equipment. This method uses X-ray electronic computer tomography (CT) devices and medical magnetic resonance imaging equipment, digital subtraction angiography X-ray machines of 800 mA or more as the management products of large-scale medical equipment, Purchase and use need to be reported to the provincial health administrative department for approval before approval. However, in recent years, with the comprehensive coverage of medical insurance, such basic medical facilities are being widely popularized, and the relevant implementation rules have directly linked the number of equipment to the number of doctors. Therefore, as the demand for imaging equipment continues to increase, it will have a greater boosting effect on the upstream contrast agent and its raw material market.[[(1R)-2-(6-aMino-9H-purin-9-yl)-1-Methylethoxy]Methyl]-, Monophenylester supplier Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders.2-Amino-5-cyanobenzotrifluoride vendor Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders.The company’s pharmaceutical intermediate business is expected to maintain a growth rate of more than 30%.